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Abstract
Agonists of TRPA1 such as mustard oil and its key component AITC cause pain and neurogenic
inflammation in humans and pain behavior in rodents. TRPA1 is activated by numerous reactive
compounds making it a sensor for reactive compounds in the body. Failure of AITC, formalin and
other reactive compounds to trigger pain behavior in TRPA1 knockout mice, as well as the ability
of TRPA1 antisense to alleviate cold hyperalgesia after spinal nerve ligation, suggest that TRPA1 is
a potential target for novel analgesic agents. Here, we have characterized CHO cells expressing
human and rat TRPA1 driven by an inducible promoter. As reported previously, both human and
rat TRPA1 are activated by AITC and inhibited by ruthenium red. We have also characterized
noxious cold response of these cell lines and show that noxious cold activates both human and rat
TRPA1. Further, we have used CHO cells expressing human TRPA1 to screen a small molecule
compound library and discovered that 'trichloro(sulfanyl)ethyl benzamides' (AMG2504, AMG5445,
AMG7160 and AMG9090) act as potent antagonists of human TRPA1 activated by AITC and
noxious cold. However, trichloro(sulfanyl)ethyl benzamides' (TCEB compounds) displayed
differential pharmacology at rat TRPA1. AMG2504 and AMG7160 marginally inhibited rat TRPA1
activation by AITC, whereas AMG5445 and AMG9090 acted as partial agonists. In summary, we
conclude that both human and rat TRPA1 channels show similar AITC and noxious cold activation
profiles, but TCEB compounds display species-specific differential pharmacology at TRPA1.
Background
The plant irritant materials such as mustard oil and was-
abi are known to cause rapid intense burning sensation
[1-3]. Mustard oil causes pain in humans and pain behav-
ior in rodents by excitation of sensory nerve fibers in part
due to neurogenic inflammation through release of neu-
ropeptides such as substance P and CGRP and other trans-
mitters from activated nerve endings [3]. The active
ingredient in mustard oil, allyl isothiocyanate (AITC)
selectively activates a non-selective cation channel, tran-
sient receptor potential ankyrin 1 (TRPA1) expressed in
the small neurons of the dorsal root and trigeminal gan-
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glia [4,5]. Interestingly, other plant irritant compounds
such as allicin from garlic and cinnamaldehyde from cin-
namon also activate TRPA1 [5-7]. Since these compounds
are capable of forming covalent adducts with thiols, other
reactive compounds such as acrolein, iodo-acetamide, N-
methylmaleimide, and several others were evaluated and
shown to activate TRPA1 through reversible covalent
modification of cystenies in the intracellular loops of
TRPA1 [8-11]. These studies resulted in the proposal that
TRPA1 acts as a sensor for reactive chemicals in the body
[12,13]. In agreement with this hypothesis, recently, it
was reported that 4-hydroxynonenal, an endogenous
aldehyde causes pain and neurogenic inflammation
through activation of TRPA1 [14].
In addition to reactive chemical activators, mechanical
stimuli and noxious cold have been shown to activate
TRPV1 in recombinant expression systems [15,16]. Reac-
tive chemicals such as AITC did not cause pain behavior
in TRPA1 knockout mice, unequivocally confirming that
their actions are mediated exclusively by TRPA1 [9,17].
On the other hand, noxious cold effect in TRPA1 knock-
out mice from two different labs differed [9,17,18], ques-
tioning the validity of noxious cold activation of TRPA1.
However, recent studies clearly showed that noxious cold
indeed activates TRPA1 in calcium imaging experiments
as well as in single channel recordings [19].
Formalin model is widely used to assess pain and to eval-
uate analgesic drugs in rodents. Recently, formalin was
reported to directly activate TRPA1 and mediate the for-
malin-induced pain behaviors [20]. Both Phase I and
Phase II pain behaviors were attenuated in TRPA1 knock-
out mice. In addition, TRPA1 expression induced in sen-
sory neurons was reported to contribute to cold
hyperalgesia after inflammation and nerve injury [21],
and antisense knock down of TRPA1 reported to alleviate
cold hyperalgesia after spinal nerve ligation in rats [22]. In
all, these studies suggest that TRPA1 is a target to identify
potential novel analgesics. In our attempts to discover the
TRPA1 antagonists, we have used CHO cells recom-
binantly expressing TRPA1 channels to screen a com-
pound library and found that 'trichloro(sulfanyl)ethyl
benzamides' (TCEB compounds; Fig. 1) act as potent and
selective antagonists of human TRPA1. Here, we report
the pharmacological characterization of TCEB com-
pounds effects on chemical ligand and noxious cold acti-
vation of human and rat TRPA1.
Results
Characterization of CHO cells expressing human and rat 
TRPA1
To identify novel TRPA1 antagonists we have established
high throughput luminescence readout based functional
assays utilizing stable CHO cell lines expressing aequorin
cDNA under control of constitutively active promoter and
human or rat TRPA1 cDNAs under control of tetracycline
inducible promoter. This enabled ad hoc expression of
TRPA1 channels for cell based assays without the poten-
tial toxic effects of constitutive expression of TRPA1 dur-
ing freezing and thawing of the cells. To characterize our
cell lines we began by testing their functional activity in
luminescence based Ca2+ influx assay. Addition of TRPA1
agonist AITC to the cells increased luminescence signal in
a concentration-dependent manner (Fig. 2A). EC50 values
for AITC activation of human and rat TRPA1 channels
were 20 ± 5 and 14 ± 3 μM respectively. Based on these
results we selected 80 μM AITC to be used for activation of
TRPA1 in all antagonist experiments. We then examined
the ability of a pore blocker, ruthenium red, to inhibit
Chemical structures of compounds used in these studies Figure 1
Chemical structures of compounds used in these studies.
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AITC activation (Fig. 2B). Ruthenium red inhibited AITC
activation of both human and rat TRPA1 with IC50 values
of 29 ± 6 and 937 ± 233 nM, respectively.
Since our automated FLASH luminometer was not
equipped for noxious cold activation assays, we employed
noxious cold-induced 45Ca2+ uptake to monitor TRPA1
activation. First, we evaluated human TRPA1 temperature
activation profile (Fig. 2C). We compared 45Ca2+ uptake in
CHO cells expressing human TRPA1 and in untransfected
CHO cells exposed to temperatures between 3.5 and
25°C. Maximum response was observed in TRPA1
expressing CHO cells incubated at 3.5–4.2°C. Minimal
induction of 45Ca2+ uptake by untrasfected CHO cells was
observed at noxious cold (3–5 to 7°C), however cells
expressing TRPA1 showed a four to five-fold higher activa-
Characterization of CHO cell lines stably expressing human and rat TRPA1 Figure 2
Characterization of CHO cell lines stably expressing human and rat TRPA1. FLASH luminometer was used to measure (A) 
concentration-dependent AITC-induced increase in intracellular calcium, and (B) concentration-dependent inhibition of AITC 
(80 μM) activation by ruthenium red in CHO cells expressing human and rat TRPA1. Each point in the graph is an average ± 
SEM of an experiment conducted in triplicate. Maximum response of AITC (80 μM) was normalized to 100%. Cold activation 
profiles of CHO cells expressing human and rat TRPA1 were characterized utilizing cold-induced 45Ca2+ uptake assay. (C) 
45Ca2+ uptake by CHO cells and CHO cells transfected with human TRPA1 in response to stimulation with temperatures 
between 3.5 and 25°C. (D) Cold temperature (4°C) activation of un-induced and tetracycline-induced CHO cells transfected 
with either human or rat TRPA1. (E) Concentration-dependent inhibition of cold (4°C) activation by ruthenium red in CHO 
cells expressing human and rat TRPA1. Each point in the graph is an average ± SEM of an experiment conducted in duplicate.
3.5 4.2 7.0 8.0 12.0 25
0
1000
2000
3000
4000
hTRPA1-CHO
CHO
Temperature, oC
4
5
C
a
2
+
 
u
p
t
a
k
e
-8 -7 -6 -5 -4 -3
0
25
50
75
100
125
hTRPA1
rTRPA1
AITC, log(M)
%
 
m
a
x
 
r
e
s
p
o
n
s
e
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
125
hTRPA1
rTRPA1
Ruthenum red, log(M)
%
 
m
a
x
 
r
e
s
p
o
n
s
e
B A
C D
hTRPA1 rTRPA1
0
1000
2000
3000
4000
5000
6000
7000
+Tet
-Tet
4
5
C
a
2
+
 
u
p
t
a
k
e
Cold activation
E
ATIC activation
Cold activation
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
125
150
hTRPA1
rTRPA1
RR, log(M)
%
m
a
x
4
5
C
a
2
+
 
u
p
t
a
k
e
Agonist response curveMolecular Pain 2007, 3:39 http://www.molecularpain.com/content/3/1/39
Page 4 of 11
(page number not for citation purposes)
tion at the same temperatures in this assay (Fig. 2C). Fur-
ther more, there was an apparent temperature drop
dependent increase in 45Ca2+ uptake in CHO expressing
cells expressing human TRPA1. In addition, we also com-
pared response of tetracycline induced versus un-induced
human and rat TRPA1 transfected CHO cells to noxious
cold in 45Ca2+ uptake assay (Fig. 2D). Six to ten-fold
increase in 45Ca2+ uptake was observed in tetracycline
induced cells, suggesting that activation by noxious cold is
in fact due to expression of human and rat TRPA1 (Fig.
2D). Next, we evaluated the ability of ruthenium red to
inhibit noxious cold activation of TRPA1 (Fig. 2E). Ruthe-
nium red inhibited noxious cold-induced 45Ca2+ uptake in
CHO cells expressing both human and rat TRPA1 in a con-
centration-dependent manner with IC50 values of 67 ± 4
nM, and 959 ± 26 nM, respectively.
Trichloro(sulfanyl)ethyl benzamides are potent 
antagonists of human TRPA1 activated by AITC
In order to screen the small molecule libraries, CHO cells
expressing human TRPA1 seeded in 96-well plates were
first incubated with 10 μM concentration of individual
compounds for one minute to evaluate potential agonism
followed by the addition of 80 μM AITC to evaluate antag-
onist properties for another minute. Compounds that did
not display partial agonist activity but exhibited inhibi-
tion of AITC-induced calcium influx were characterized
further. During this process, we have discovered that four
molecules representing trichloro(sulfanyl)ethyl benza-
mides completely inhibited human TRPA1 activation.
Further, we evaluated concentration-dependent effects of
TCEB compounds on AITC activation of human TRPA1 in
CHO cells (Fig. 3A–D). All four TCEB compounds
potently and concentration-dependently inhibited AITC-
induced increase in intracellular calcium mediated by
TRPA1. The IC50  values determined for AMG9090,
AMG5445, AMG2504 and AMG7160 were 21 ± 0.6, 91 ±
39, 35 ± 29 and 51 ± 17 nM, respectively. All four TCEB
compounds' did not induce any calcium uptake through
activation of TRPA1 in these assays, suggesting that these
are not partial agonists of TRPA1 (Fig. 3A–D). In addition,
we evaluated all four TCEB compounds in electrophysiol-
ogy, using whole cell voltage-clamp configuration (Fig.
4A–D). In this assay, as predicted, all four TCEB com-
pounds inhibited AITC-induced currents in a concentra-
tion-dependent manner with IC50 values of 120 ± 31, 260
± 101, 167 ± 55 and 252 ± 73 nM for AMG9090,
AMG5445, AMG2504 and AMG7160, respectively. Two
most potent TCEB compounds at inhibiting AITC activa-
tion of human TRPA1 in both aequorin based lumines-
cence and electrophysiology assays were AMG9090 and
AMG2504.
Our efforts to characterize the nature of TCEB compounds
inhibition of AITC activation and to determine the disso-
ciation constants for TCEB compounds were not success-
ful (data not shown). For example, all four TCEB
compounds did not shift the concentration response
curves of AITC to right, however showed attenuation of
maximum response. We believe these results were con-
founded by the nature of AITC activation of TRPA1, which
acts by covalent modification of intracellular cysteines to
activate the TRPA1 channels [8].
We have also evaluated the selectivity profile of TCEB
compounds among closely related TRP channels. TCEB
compounds were found to be selective for TRPA1 among
the recombinant TRP family members that we have tested
(Table 1). The IC50 value for all four TCEB compounds
were >20 μM except AMG9090 against capsaicin activated
TRPV1, 2-APB activated TRPV3, 4-αPDD activated TRPV4,
and icilin activated TRPM8 in cell based assays that meas-
ure agonist-induced increases in intracellular calcium in
CHO cells recombinantly expressing the appropriate TRP
channel. AMG9090 inhibited TRPM8 with an IC50 value
of 2.43 μM.
TCEB compounds are potent antagonists of human TRPA1 
activated by noxious cold
Since noxious cold (3.5 and 4.2°C) induced a significant
45Ca2+ uptake into CHO cells in a TRPA1 dependent man-
ner, we evaluated the ability of TCEB compounds to
inhibit this response. In this assay, all four TCEB com-
pounds inhibited human TRPA1 activation by 3.5°C tem-
perature. The IC50  values determined for AMG9090,
AMG5445, AMG2504 and AMG7160 are 7 ± 0.3, 29 ± 6,
105 ± 9 and 28 ± 0.26 nM, respectively (Fig. 5). The rank
order of potency for these compounds inhibiting noxious
cold activation was AMG9090 > AMG7160 = AMG5445 >
AMG2504. In general, it appears that these compounds
are more potent at inhibiting noxious cold activation of
TRPA1 compared to AITC (compare figures 3 and 5).
Differential pharmacology of TCEB compounds at rat 
TRPA1
Before evaluating TCEB compounds ability to inhibit rat
TRPA1 activation, we tested their potential agonism in
CHO cells expressing TRPA1. Surprisingly, AMG9090 and
AMG5445 induced an increase in intracellular calcium in
a concentration dependent manner, suggesting that they
are partial agonists at rat TRPA1 (Fig. 6A). Compared to
80 μM AITC efficacy, maximum efficacy of AMG9090 was
approximately 50% and EC50 value was 66 ± 11 nM. Sim-
ilarly, maximum efficacy of AMG5445 was approximately
35% with an EC50 value of 115 ± 70 nM. In contrast,
AMG2504 and AMG7160 did not induce an increase in
intracellular calcium up to 50 μM, suggesting that they are
not partial agonists (Fig. 6A). We next examined the abil-Molecular Pain 2007, 3:39 http://www.molecularpain.com/content/3/1/39
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Trichloro(sulfanyl)ethyl benzamides inhibit AITC (80 μM) induced increase in intracellular calcium and inward currents in CHO  cells stably expressing human TRPA1 (A-D) Figure 3
Trichloro(sulfanyl)ethyl benzamides inhibit AITC (80 μM) induced increase in intracellular calcium and inward currents in CHO 
cells stably expressing human TRPA1 (A-D). Effect of AMG9090 (A), AMG5445 (B), AMG2504 (C), and AMG7160 (D) on 
AITC-induced increase in intracellular calcium in CHO cells expressing human TRPA1 measured in an aequorin-readout assay. 
Open circles represent the response of cells to the compound itself in the absence of agonist. Each point in the graph is an 
average ± SEM of an experiment conducted in triplicate.
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ity of AMG2504 and AMG7160 to inhibit AITC activation
of rat TRPA1. Both compounds showed marginal inhibi-
tion of AITC-induced increase in intracellular calcium
(IC50 value is > 30 μM; Fig. 6E).
We further examined all four TCEB compounds in electro-
physiology, using whole cell voltage-clamp configuration.
Correlating with agonist-induced aequorin based lumi-
nescence read out, both AMG9090 and AMG5445
induced inward currents in CHO cells expressing TRPA1,
confirming their partial agonism (Fig. 6C,D). Further,
AMG2504 and AMG7160 neither inducing any inward
currents by themselves nor significantly blocked currents
generated by 80 μM AITC (Fig. 6FG), confirming the
observations seen in assays that measured agonist-
induced aequorin based luminescence. In summary,
TCEB compounds exhibited exactly same differential
pharmacology at rat TRPA1 in two different cell based
assays.
Table 1: Effects of trichloro(sulfanyl)ethyl benzamides on 
capsaicin activation of TRPV1, icilin-activated TRPM8, 2-APB-
activated TRPV3 and 4α-PDD-induced TRPV4. The ability of 
compounds to inhibit channel activation was evaluated up to a 
maximum concentration of 5 μM.
Compound hTRPV1 hTRPM8 hTRPV3 hTRPV4
AMG9090 >5 2.43 >5 >5
AMG5445 ND >5 >5 >5
AMG2504 >5 >5 >5 >5
AMG7160 >5 >5 >5 >5
Trichloro(sulfanyl)ethyl benzamides inhibit AITC (80 μM) induced inward currents in CHO cells stably expressing human  TRPA1 Figure 4
Trichloro(sulfanyl)ethyl benzamides inhibit AITC (80 μM) induced inward currents in CHO cells stably expressing human 
TRPA1. Representative traces of inward currents evoked by AITC in the absence or presence of AMG9090 (A), AMG5445 
(B), AMG2504 (C), and AMG7160 (D) are shown. IC50 value for each compound was determined from their concentration-
dependent inhibition of AITC-induced currents using a PatchXpress 7000A workstation.
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Discussion
TRPA1 expression induced in sensory neurons was
reported to contribute to cold hyperalgesia after inflam-
mation and nerve injury [21], and antisense knock down
of TRPA1 reported to alleviate cold hyperalgesia after spi-
nal nerve ligation in rats [22]. In addition, agonists of
TRPA1 cause pain in humans [3] and pain behavior in
wild type but not in TRPA1 knockout mice [9,17]. Based
on above observations, TRPA1 is considered as a promis-
ing target for identification of analgesic drugs. To identify
TRPA1 antagonists, first, we generated CHO cells stably
integrated with TRPA1 cDNA under a tetracycline induci-
ble expression vector. We then characterized both human
and rat TRPA1 expression in CHO cells by measuring
AITC-induced increases in intracellular calcium and the
ability to inhibit this response by ruthenium red.
Although noxious cold activation of TRPA1 is somewhat
controversial [4,16], recently it has been proven that nox-
ious cold activates TRPA1 channels characterized by cal-
cium imaging as well as single channel recordings [19]. To
evaluate if noxious cold activates TRPA1 channels in our
experimental conditions, we employed a radioactive cal-
cium uptake assay in native CHO cells as well as CHO
cells that express TRPA1 and confirmed that noxious cold
indeed activates both human and rat TRPA1. We have also
confirmed noxious cold activation of TRPA1 by evaluating
un-induced and tetracycline-induced CHO cells trans-
fected with TRPA1, which showed that noxious cold
induces significant 45Ca2+ influx only into tetracycline-
induced CHO cells transfected with TRPA1. Further, we
showed that noxious cold-induced 45Ca2+  influx was
inhibited by ruthenium red. In summary, these studies
confirm that both human and rat TRPA1 are activated by
AITC and noxious cold and a pore blocker, ruthenium red
inhibits both.
Since we are interested in identifying TRPA1 antagonists,
we employed a 96-well format HTS assay to screen com-
pound libraries and identified four TCEB compounds
(AMG2504, AMG5445, AMG7160 and AMG9090) as
potent antagonists of human TRPA1 activation by AITC.
We further confirmed the antagonism of TCEB com-
pounds at human TRPA1 by electrophysiology studies
that demonstrated similar IC50 values, indicating TCEB
compounds are the most potent TRPA1 antagonists
reported to date. In addition, all four compounds inhib-
ited noxious cold-activated human TRPA1 channels sug-
gesting that this series of antagonists inhibit two distinct
modes of TRPA1 activation. Based on the structures of
TCEB compounds, un-substituted phenyl on the amide
seems to give greater potency to inhibit AITC activation of
human TRPA1. In addition, all three substitutions (4-
methoxy phenyl, 4-bromophenyl, and 4-nitrophenyl) at
this position did not alter the potency significantly at
human TRPA1 channels.
We do not know where these molecules interact within
the TRPA1 channel, or if they act as antagonists by modi-
fying the intracellular cysteines so that agonists no longer
modify them to activate the channel. Our attempts to
determine the dissociation constants for these com-
pounds did not show a clear pattern of whether these
compounds are competitive antagonists of AITC. This is
further complicated by the fact that AITC activates the
TRPA1 channel by intracellular cysteine modifications.
Further, it is not known where icilin binds on the TRPA1
channel and what critical residues are required for icilin
and noxious cold activation. Chemical ligands are known
to interact within the transmembrane domains 2 to 4
region for the other well studied TRP channels such as
TRPV1 [23-25], TRPM8 [26]and TRPV4 [27], but critical
residues for heat activation are still unknown. In the
absence of such details for TRPA1, we can only predict
that TCEB series of antagonists probably lock the channel
conformation in the closed or non-conducting state so
that neither chemical agonists such as AITC nor noxious
cold can activate this channel.
Recently, it was reported that calcium directly activates
TRPA1 channels [28,29]. It is possible that noxious cold
can release intracellular calcium or induce extracellular
calcium uptake that might activate TRPA1. In our studies
noxious cold did induce uptake of a small amount of extra
cellular calcium into CHO cells, however, uptake was four
Trichloro(sulfanyl)ethyl benzamides inhibit cold temperature  (4°C) induced 45Ca2+ uptake in CHO cells stably expressing  human TRPA1 Figure 5
Trichloro(sulfanyl)ethyl benzamides inhibit cold temperature 
(4°C) induced 45Ca2+ uptake in CHO cells stably expressing 
human TRPA1. Concentration-response curves were gener-
ated utilizing 45Ca2+ uptake assays as described under Materi-
als and Methods. Each point in the graph is an average ± SEM 
of an experiment conducted in duplicate.
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to five-fold higher in TRPA1 expressing cells. Since selec-
tive antagonists of TRPA1 potently inhibited noxious
cold-induced  45Ca2+ uptake into CHO cells expressing
TRPA1, we believe that noxious cold does activate TRPA1.
Since we cannot completely rule out the contribution of
calcium directly activating TRPA1 channels during nox-
ious cold application, it is possible that both calcium and
noxious cold might have contributed to TRPA1 activation
and concomitant 45Ca2+ uptake in our studies. However,
TCEB compounds inhibit this 45Ca2+ uptake completely
confirming that all noxious cold-induced 45Ca2+ uptake
was TRPA1 mediated.
All four TCEB compounds that we report here inhibited
both AITC and noxious cold activation of human TRPA1
but exhibited differential pharmacology at rat TRPA1.
AMG9090 and AMG5445 acted as partial agonists
whereas AMG2504 and AMG7160 showed a marginal
antagonism at rat TRPA1. It is interesting that modifica-
tions on the phenyl group on amide on the right hand
side do not seem to affect the antagonism of human
TRPA1 significantly and by inference the way they interact
with the TRPA1 channels to inhibit AITC or cold activa-
tion. However, the same modifications dramatically
affected the effects of these molecules at rat TRPA1. For
example, un-substituted phenyl in AMG9090 and 4-
methoxy phenyl in AMG5445 on amide resulted in partial
agonism at rat TRPV1 for these two compounds. Further-
more, 4-bromophenyl in AMG7160 and 4-ntrophenyl in
AMG2504 on amide did not result in partial agonism but
made them almost ineffective against AITC activation of
TRPA1. As we mentioned earlier for mechanism(s) of
Effect of human TRPA1 antagonists on CHO cells stably expressing rat TRPA1 Figure 6
Effect of human TRPA1 antagonists on CHO cells stably expressing rat TRPA1. (A) Concentration-response curves generated 
in aequorin-readout assay Note, AMG9090 and AMG5445 acted as partial agonists. Each point in the graph is presented as per-
cent of AITC response and is an average ± SEM of an experiment conducted in triplicate. Representative traces of inward cur-
rents induced by AITC, AMG9090 and AMG5445 are shown in B, C, and D respectively. (E) AITC-induced increase in 
intracellular calcium in CHO cells expressing rat TRPA1 in the absence (100%) or presence of different concentrations of 
AMG2504 and AMG 7160. Representative current traces induced by AITC in the presence of AMG2504 and AMG 7160 are 
shown in F and G, respectively.
-10 -9 -8 -7 -6 -5 -4
0
25
50
75
100
125
AMG2504
AMG7160
Compound, log(M)
%
 
m
a
x
 
r
e
s
p
o
n
s
e
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
AMG9090
AMG5445
AMG2504
AMG7160
Compound, log(M)
P
O
C
A
E
10  M
AMG7160
80  M
AITC
0.5nA
25s
10  M
AMG2504
80  M
AITC
25s
0.5nA
10  M
AMG9090
0.5 nA
10 s
10  M
AMG5445
0.25 nA
10 s
80  MA I T C
0.5 nA
10 s
BCD
FGMolecular Pain 2007, 3:39 http://www.molecularpain.com/content/3/1/39
Page 9 of 11
(page number not for citation purposes)
human TRPA1 antagonism, it is unclear how these modi-
fications affect their interactions with rat TRPA1 or how
such dramatic effects can arise from their interaction with
rat TRPA1. Since we have confirmed the results in two
independent readouts (i.e., by assays that measure ago-
nist-induced increase in intracellular calcium and by elec-
trophysiology methods), we believe the observed effects
of these compounds at rat TRPA1 are not experimental
artifacts.
Recently, significant initial progress has been made
toward identifying TRPA1 antagonists that will help eval-
uate their utility as pain therapeutics. One of these studies
demonstrated that TRPA1 mediates the formalin-induced
pain, by showing that responses to formalin were attenu-
ated in TRPA1 knockout mice and that pharmacological
blockade of TRPA1 by a novel antagonist attenuates for-
malin-induced pain behaviors in rodents. Further,
another TRPA1 antagonist was shown to inhibit CFA-
induced mechanical allodynia (Ardem Patapoutian,
Spring Pain Conference, 2006, Grand Cayman, BWI), sug-
gesting that TRPA1 might play a role in inflammatory
pain. TRPA1 antagonist effects in neuropathic pain mod-
els are yet to be determined. Further studies should reveal:
i) identification of the binding pocket for non-reactive
agonists and antagonists, ii) key residues involved in nox-
ious cold activation, iii) how the antagonist interactions
with the TRPA1 affect both chemical ligand and noxious
cold activation, and iv) the utility of TRPA1 antagonists as
analgesics.
Methods
The details of cDNA sequences used for generation of sta-
ble cell lines were described recently in Gavva et al., 2007.
All the cell culture reagents were purchased from Invitro-
gen (Carlsbad, CA). All compounds used in the study are
shown in Figure 1.
Luminescence readout assay for measuring intracellular 
calcium
Stable CHO cell lines expressing human TRPA1, TRPM8,
TRPV3, TRPV4 and rat TRPA1 were generated using tetra-
cycline inducible T-REx™ expression system from Invitro-
gen, Inc (Carlsbad, CA). Generation of stable CHO cells
expressing human TRPV1 was described previously in
Gavva et al., 2005. In order to enable a luminescence rea-
dout based on intracellular increase in calcium [30], each
cell line was also co-transfected with pcDNA3.1 plasmid
containing jelly fish aequorin cDNA. Twenty four hours
before the assay, cells were seeded in 96-well plates (Corn-
ing, Inc) and TRP channel expression was induced with
0.5 μg/ml tetracycline. On the day of the assay, culture
media was removed and cells were incubated with assay
buffer (F12 containing 30 mM HEPES for TRPA1, TRPM8,
TRPV1 and TRPV3; F12 containing 30 mM HEPES, 1 mM
CaCl2, and 0.3% BSA for TRPV4) containing 15 μM coe-
lenterazine (P.J.K, Germany) for 2 hours. Antagonists
were added for 2.5 min prior to addition of an agonist.
The luminescence was measured by a CCD camera based
FLASH-luminometer built by Amgen, Inc. The following
agonists were used to activate TRP channels: 80 μM AITC
for TRPA1, 1 μM icilin for TRPM8, 0.5 μM capsaicin for
TRPV1, 200 μM 2-APB for TRPV3, and 1 μM 4α-PDD for
TRPV4. Luminescence signal was captured for 1 min after
compound addition and for 1 min after the agonist addi-
tion, thus generating agonism and antagonism data for
each compound from the same assay. Compound activity
was calculated using GraphPad Prism 4.01 (GraphPad
Software Inc, San Diego, CA).
Cold antagonism assay (45Ca2+ uptake)
Twenty four hours before the assay, cells were seeded in
96-well plates (Amersham) and TRPA1 expression was
induced with 0.5 μg/ml tetracycline. Cold activation of
TRPA1 was followed as a function of cellular uptake of
radioactive calcium (45Ca2+, Perkin Elmer). All the 45Ca2+
uptake assays had a final 45Ca2+ concentration of 10 μCi/
ml. The Cold antagonist assay was performed as follows:
Compounds were pre-incubated for 1 min at room tem-
perature with CHO cells expressing TRPA1 in F-12
medium supplemented with BSA, 0.1 mg/ml, and 15 mM
HEPES. 45Ca2+ was added in F-12 and the plates were left
on a chilling plate unit (Torrey Pines ECHO Therm) for 12
min allowing the final temperature of 3.5°C to be
reached. Plates were washed twice with phosphate-buff-
ered saline containing 0.1 mg/ml BSA. Radioactivity was
measured using a MicroBeta Jet (Perkin-Elmer Inc). Data
were analyzed using GraphPad Prism 4.01 (GraphPad
Software Inc., San Diego, CA). Maximum 45Ca2+ uptake in
response to cold was considered as 100% in calculating
the IC50 values.
Electrophysiology
CHO cells expressing hTRPA1 or rTRPA1 were studied by
whole-cell voltage-clamp recording using an automated
PatchXpress 7000A workstation (Axon Instruments, now
part of Molecular Devices). The cells were grown in T-75
flasks with ~70% confluence and the hTRPA1 or rTRPA1
were induced for 24 hours with 0.5 ug/ml tetracycline
prior experiment. Cell suspensions were prepared with
normal splitting procedure with the use of 0.05% Trypsin-
EDTA. The cells were allowed to recover in culture media
at 37°C for half an hour before they were re-suspended in
extracellular recording solution for final recording. The
extracellular recording solution contained (in mM): 62.5
CsCl, 75 CsF, 2.5 MgCl2, 10 HEPES, 5 EGTA, pH 7.2. The
intracellular recording solution contained (in mM): 140
NaCl, 5 KCl, 2 CaCl2, 1.1 MgCl2, 10 HEPES, 11 Glucose,
pH 7.4. Experiments were performed at a holding poten-
tial of -70 mV with a predefined voltage-clamp protocol.Molecular Pain 2007, 3:39 http://www.molecularpain.com/content/3/1/39
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Once the protocol was triggered the PatchXpress automat-
ically load the cells and add the test compounds in
designed sequence. Under this experimental condition
the activation of hTRPA1 or rTRPA1 produced inward cur-
rent. AITC (80 uM) was used to serve as a control agonist
for both hTRPA1 and rTRPA1 channels. The data were
recorded on a computer hard disk and the analysis was
performed off line with Clampfit software (Axon Instru-
ments, now part of Molecular Devices).
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